ZyVersa Therapeutics (ZVSA) Competitors $0.14 -0.01 (-9.00%) As of 03:29 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZVSA vs. BDRX, SHPH, ADTX, TRIB, DRMA, REVB, SPRC, ARTL, INDP, and ARAVShould you be buying ZyVersa Therapeutics stock or one of its competitors? The main competitors of ZyVersa Therapeutics include Biodexa Pharmaceuticals (BDRX), Shuttle Pharmaceuticals (SHPH), Aditxt (ADTX), Trinity Biotech (TRIB), Dermata Therapeutics (DRMA), Revelation Biosciences (REVB), SciSparc (SPRC), Artelo Biosciences (ARTL), Indaptus Therapeutics (INDP), and Aravive (ARAV). These companies are all part of the "pharmaceutical products" industry. ZyVersa Therapeutics vs. Its Competitors Biodexa Pharmaceuticals Shuttle Pharmaceuticals Aditxt Trinity Biotech Dermata Therapeutics Revelation Biosciences SciSparc Artelo Biosciences Indaptus Therapeutics Aravive ZyVersa Therapeutics (NASDAQ:ZVSA) and Biodexa Pharmaceuticals (NASDAQ:BDRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation. Which has preferable earnings and valuation, ZVSA or BDRX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZyVersa TherapeuticsN/AN/A-$9.41MN/AN/ABiodexa PharmaceuticalsN/AN/A-$7.32MN/AN/A Do institutionals and insiders hold more shares of ZVSA or BDRX? 3.9% of ZyVersa Therapeutics shares are owned by institutional investors. Comparatively, 17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. 0.2% of ZyVersa Therapeutics shares are owned by company insiders. Comparatively, 0.3% of Biodexa Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more risk and volatility, ZVSA or BDRX? ZyVersa Therapeutics has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, Biodexa Pharmaceuticals has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Does the media favor ZVSA or BDRX? In the previous week, Biodexa Pharmaceuticals had 2 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 2 mentions for Biodexa Pharmaceuticals and 0 mentions for ZyVersa Therapeutics. Biodexa Pharmaceuticals' average media sentiment score of 0.96 beat ZyVersa Therapeutics' score of 0.00 indicating that Biodexa Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment ZyVersa Therapeutics Neutral Biodexa Pharmaceuticals Positive Do analysts prefer ZVSA or BDRX? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZyVersa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Is ZVSA or BDRX more profitable? Biodexa Pharmaceuticals' return on equity of 0.00% beat ZyVersa Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ZyVersa TherapeuticsN/A -109.54% -43.95% Biodexa Pharmaceuticals N/A N/A N/A SummaryBiodexa Pharmaceuticals beats ZyVersa Therapeutics on 9 of the 9 factors compared between the two stocks. Get ZyVersa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVSA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZVSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZVSA vs. The Competition Export to ExcelMetricZyVersa TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.08M$3.32B$6.01B$10.23BDividend YieldN/A2.29%5.66%4.69%P/E RatioN/A22.1185.3526.57Price / SalesN/A416.63582.95179.01Price / CashN/A47.1938.3262.20Price / Book0.0410.2112.726.53Net Income-$9.41M-$52.40M$3.30B$275.87M7 Day Performance-14.74%0.90%1.07%-1.40%1 Month Performance-16.97%12.36%7.61%5.16%1 Year Performance-94.19%30.17%79.71%31.51% ZyVersa Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZVSAZyVersa TherapeuticsN/A$0.14-9.0%N/A-93.6%$1.08MN/A0.002Gap DownBDRXBiodexa Pharmaceuticals0.3779 of 5 stars$6.65-0.6%N/A-77.2%$4.12M$470K0.0020Gap DownSHPHShuttle Pharmaceuticals0.7898 of 5 stars$3.55-6.6%N/A-81.5%$3.80MN/A-0.865News CoveragePositive NewsTrading HaltedADTXAditxtN/A$0.75-8.8%N/A-99.8%$3.75M$130K0.0060Positive NewsAnalyst ForecastTRIBTrinity Biotech0.7035 of 5 stars$1.04-1.0%N/A-86.9%$3.74M$61.56M-0.07480Positive NewsAnalyst ForecastDRMADermata Therapeutics2.5632 of 5 stars$5.02-3.5%$10.00+99.2%-66.6%$3.41MN/A-0.318Positive NewsAnalyst ForecastREVBRevelation Biosciences1.5194 of 5 stars$1.42-0.7%N/A-96.2%$3.32MN/A-0.0210Positive NewsSPRCSciSparc0.8473 of 5 stars$6.04+35.4%N/A+3.7%$3.23M$1.31M0.004Analyst ForecastGap UpHigh Trading VolumeARTLArtelo Biosciences2.97 of 5 stars$4.59-21.5%$24.00+422.9%-27.5%$3.21MN/A-0.245Analyst ForecastGap DownINDPIndaptus Therapeutics2.1034 of 5 stars$2.87-4.0%$238.00+8,192.7%-86.1%$3.18MN/A-0.086Analyst ForecastARAVAraviveN/A$0.04flatN/AN/A$2.95M$6.99M0.0020High Trading Volume Related Companies and Tools Related Companies BDRX Alternatives SHPH Alternatives ADTX Alternatives TRIB Alternatives DRMA Alternatives REVB Alternatives SPRC Alternatives ARTL Alternatives INDP Alternatives ARAV Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZVSA) was last updated on 10/10/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenIf you're a futures trader (or want to be one), this could be the biggest shift you'll ever see in the prop fi...Neuro Street Trading Academy | SponsoredThe best AI stock you aren’t watching (but Elon is)Elon Musk's AI empire is already being built... not in the spotlight, but in the background. One public cou...Behind the Markets | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredU.S. Government Sparking Crypto RallyAltcoin ETFs could surge prices (do this now) My "Crypto Bull Run Millionaire Blueprint" breaks down exactl...Crypto 101 Media | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredMiss This IRS Strategy Now, Regret It LaterWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZyVersa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ZyVersa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
